PDT Partners LLC Buys Shares of 37,110 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

PDT Partners LLC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 37,110 shares of the specialty pharmaceutical company's stock, valued at approximately $1,157,000. PDT Partners LLC owned approximately 0.07% of Supernus Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of SUPN. Armistice Capital LLC lifted its position in shares of Supernus Pharmaceuticals by 47.6% during the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company's stock worth $141,026,000 after purchasing an additional 1,700,000 shares in the last quarter. Pacer Advisors Inc. boosted its position in Supernus Pharmaceuticals by 100,186.3% in the 2nd quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company's stock valued at $36,109,000 after buying an additional 1,348,508 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Supernus Pharmaceuticals by 369.1% in the 2nd quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company's stock valued at $13,419,000 after buying an additional 394,728 shares during the period. Renaissance Technologies LLC raised its position in shares of Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company's stock worth $45,077,000 after acquiring an additional 351,900 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Supernus Pharmaceuticals by 12.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company's stock valued at $76,690,000 after acquiring an additional 309,966 shares during the period.

Analyst Ratings Changes

Several analysts have weighed in on the company. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Piper Sandler reaffirmed a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN traded up $0.74 during mid-day trading on Monday, hitting $37.31. The company had a trading volume of 325,173 shares, compared to its average volume of 442,911. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The firm has a market cap of $2.06 billion, a P/E ratio of 34.26 and a beta of 0.86. The business's fifty day moving average is $34.20 and its two-hundred day moving average is $31.35.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same quarter last year, the firm earned ($0.29) EPS. Supernus Pharmaceuticals's quarterly revenue was up 14.2% compared to the same quarter last year. Equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the transaction, the senior vice president now owns 8,200 shares of the company's stock, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Georges Gemayel sold 14,213 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the sale, the director now directly owns 13,315 shares of the company's stock, valued at $487,595.30. This represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock valued at $5,660,180 in the last quarter. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.